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BACKGROUND AND PURPOSE
Pancreatic cancer is characterized by alterations in several key signalling proteins, including increased expression and activity
of the Src tyrosine kinase and focal adhesion kinase (FAK), which have been linked to its chemoresistance. Sustained Src
inhibition reactivates survival pathways regulated by the transcription factor STAT3, also leading to resistance. Therefore,
simultaneously targeting Src/FAK and STAT3 signalling could provide an important strategy for treating pancreatic cancer.
Recently, we described novel quinazolinediones that increased generation of reactive oxygen species (ROS) and were cytotoxic
in pancreatic cancer cells. Here, we have investigated effects of our lead compound, QD232, on Src/FAK and STAT3 signalling.
EXPERIMENTAL APPROACH
The major signalling pathways affected by QD232 in pancreatic cancer cell lines were identified by Kinexus proteomic
analysis. Changes in key signalling proteins were confirmed by Western blotting. Cell migration was assessed by Boyden
chamber and wound healing assays. Direct inhibition of kinase activity in vitro was assayed with a panel of 92 oncogenic
kinases. Safety and efficacy of QD232 were determined in a xenograft mouse model of pancreatic cancer.
KEY RESULTS
QD232 potently inhibited Src/FAK and STAT3 phosphorylation, decreasing pancreatic cancer cell viability and migration.
Furthermore, QD232 arrested cell cycle progression and induced apoptosis in these cells at low micromolar concentrations.
Effects of QD232 on Src/FAK and STAT3 phosphorylation were blocked by N-acetylcysteine or glutathione.
CONCLUSIONS AND IMPLICATIONS
QD232 is a novel compound with a unique, ROS-dependent mechanism, effective in drug-resistant cancer cell lines. This
compound shows potential as therapy for pancreatic cancer.
Abbreviations
5-FU, 5-fluorouracil; FAK, focal adhesion kinase; IPA, Ingenuity Pathway Analysis; MTT, 3-(4,5-dimethylthiazol-2-yl)-2,5-
diphenyltetrazolium bromide; NAC, N-acetylcysteine; QD232, 6-[(3-acetylphenyl)amino]quinazoline-5,8-dione; ROS,
reactive oxygen species
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Introduction
Pancreatic cancer is one of the most lethal forms of cancer
worldwide. It has been estimated that in 2014, around 46 420
people will be diagnosed and 39 590 people will die of pan-
creatic cancer in the United States (cancer.gov, 2014a). Simi-
larly, 41 300 people will die of pancreatic cancer in the
European Union (Malvezzi et al., 2014). Late-stage detection
and chemoresistance make it difficult to treat pancreatic
cancer effectively, resulting in poor prognosis. These grim
statistics clearly demonstrate the urgent need for develop-
ment of agents with novel mechanisms of action to combat
pancreatic cancer. FOLFIRINOX [a combination regime con-
sisting of folinic acid, 5-fluorouracil (5-FU), irinotecan and
oxaliplatin] is the most commonly used drug combination
for the treatment of pancreatic cancer (cancer.gov, 2014b).
Pancreatic cancer is characterized by numerous key muta-
tions in genes of several signal transduction pathways includ-
ing signalling by the cytosolic, non-receptor tyrosine kinase,
Src. Src kinase is overactivated in several forms of cancer
where it plays an important role in regulation of cell adhe-
sion, motility, invasion, proliferation, survival and angiogen-
esis (Lutz et al., 1998; Summy and Gallick, 2003; Hilbig, 2008;
Kim et al., 2009). Recent studies have successfully validated
Src and its phosphorylated form (pSrc) as novel biomarkers
for pancreatic cancer (Yokoi et al., 2011). Increased expres-
sion, phosphorylation and activity of Src have been reported
in gemcitabine-resistant pancreatic cancer cells (Duxbury
et al., 2004a,b). Src inhibition effectively slows the growth of
human pancreatic cancer xenografts in mice (Rajeshkumar
et al., 2009), suppresses invasiveness (Ito et al., 2003), and
reverses resistance to 5-FU and gemcitabine (Duxbury et al.,
2004a,b; Ischenko et al., 2008). Combined use of Src inhibi-
tors, such as the pyrazolopyrimidine PP2 or AZM475271, and
gemcitabine results in decreased tumour growth and inhibi-
tion of metastatic spread in orthotopic xenografts of pancre-
atic cancer (Duxbury et al., 2004b; Yezhelyev et al., 2004).
Additionally, Src inhibition by PP2 can augment sensitivity to
5-FU in 5-FU-resistant pancreatic cancer cells (Ischenko et al.,
2008).
The effort to develop drugs for late-stage and highly
resistant pancreatic cancer led to the evaluation of dasatinib,
a potent Src inhibitor, in clinical trials for metastatic
and locally advanced pancreatic cancer (clinicaltrials.gov,
2014a–g). Studies have shown that dasatinib inhibits cell
proliferation, migration, invasion, and anchorage independ-
ent growth resulting in tumour growth reduction in vivo.
However, dasatinib treatment also leads to resistance because
of the lack of inhibition of signalling via the STAT3 and
MAPK pathways (Nagaraj et al., 2010). STAT3 reactivation
following Src inhibition occurs in several forms of cancer
resulting in resistance to Src inhibitors (Byers et al., 2009; Sen
et al., 2009). Therefore, there is a need to develop safe and
potent drugs with a new mechanism of action that can over-
come resistance induced by the current Src inhibitors.
Recently, we screened a large set of highly diverse com-
pounds in an assay specific for cellular respiration and dis-
covered a novel class of compounds that induced oxygen
consumption and were cytotoxic by Akt-directed generation
of reactive oxygen species (ROS), in a panel of pancreatic cell
lines (Pathania et al., 2014). Here, we have shown that the
lead compound, QD232 (referred to as compound 3b in
Pathania et al., 2014), caused a rapid and sustained inactiva-
tion of Src, focal adhesion kinase (FAK) and STAT3. Our
central hypothesis is that QD232 inhibited phosphorylation
and activation of three substrates, Src, FAK and STAT3 and
thus was able to overcome resistance to Src inhibitors. Fur-
thermore, QD232 is a novel agent with unique targets and
has biodistribution, safety and efficacy characteristics neces-
sary for further development.
Methods
Cell culture
Pancreatic cancer cell lines (MIA PaCa-2, PANC-1 and
BxPC-3) were purchased from the American Type Culture
Collection (Manassas, VA, USA). The pancreatic cancer cell
line (ASPC-1) was kindly provided by Dr Alan L. Epstein (Keck
School of Medicine, University of Southern California, Los
Angeles, CA, USA). Human foreskin fibroblast cell lines
(HFF-1) were kindly provided by Dr Carla Grandori (Fred
Hutchinson Cancer Research Center, Seattle, WA, USA)
(Wang et al., 2011). Resistant cell lines, MIA PaCa-2-GR (gem-
citabine resistant) and MIA PaCa-2-GTR (gemcitabine and
erlotinb resistant) were kindly provided by Dr Sarkar (Depart-
ment of Pathology, Wayne State University School of Medi-
cine, Detroit, MI, USA) (Soubani et al., 2012). All cell lines
used were maintained in culture under 35 (10 for HFF-1)
passages and tested regularly for Mycoplasma contamination
using Plasmo TestTM (InvivoGen, San Diego, CA, USA). Cell
lines were maintained in the appropriate growth media
[DMEM (Cellgro, Mediatech, Manassas, VA, USA) for PANC-1,
MIA PaCa-2, and RPMI-1640 (Cellgro) for ASPC-1, BxPC-3
Tables of Links
TARGETS
Src tyrosine kinase
FAK, focal adhesion kinase
LIGANDS
Dasatinib
Gemcitabine
These Tables list key protein targets and ligands in this article which are hyperlinked to corresponding entries in http://
www.guidetopharmacology.org, the common portal for data from the IUPHAR/BPS Guide to PHARMACOLOGY (Pawson et al., 2014) and are
permanently archived in the Concise Guide to PHARMACOLOGY 2013/14 (Alexander et al., 2013).
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and HFF-1] containing 10% heat-inactivated FBS (Gemini-
Bioproducts, West Sacramento, CA, USA) at 37°C in a humidi-
fied atmosphere of 5% CO2. MIA PaCa-2-GR and MIA
PaCa-2-GTR were maintained in DMEM (with 10% FBS) sup-
plemented with 200 nM gemcitabine, and 200 nM gemcit-
abine and 2 μM erlotinib (every other week), respectively. For
subculture and experiments, cells were washed with 1 × Dul-
becco’s PBS (DPBS, Cellgro), detached using 0.025% trypsin-
EDTA (Cellgro), collected in growth media and centrifuged.
All experiments were performed in growth media using sub-
confluent cells in the exponential growth phase.
Cytotoxicity assay
Cytotoxicity was assessed by a 3-(4,5-dimethylthiazol-2-yl)-
2,5-diphenyltetrazolium bromide (MTT) assay as previously
described (Pathania et al., 2014) (details in Supporting Infor-
mation Appendix S1).
Cell cycle analysis
Sub-confluent cells were seeded in 60 mm tissue culture
dishes at a density of 2 × 105 cells per plate in growth media
and allowed to adhere overnight. The following day, cells
were treated with QD232 or dasatinib or DMSO as vehicle
control. Upon completion of treatment, cells were detached
with trypsin, and both media and cells were collected by
centrifugation. Cells were washed and re-suspended in 1×
DPBS, and then fixed in 70% ethanol overnight at −20°C. For
determination of DNA content, fixed cells were washed with
1× DPBS, treated with 100 μg·mL−1 RNase A (Sigma-Aldrich,
St. Louis, MO, USA), and stained with propidium iodide
(50 μg·mL−1, Sigma-Aldrich). DNA content of the samples was
analysed by flow cytometry using the BD LSR II flow cyto-
meter (BD Biosciences, San Jose, CA, USA).
Western blotting analyses
Cells were seeded and allowed to adhere overnight. After the
desired treatment, cells were washed with 1× DPBS and lysed
using RIPA lysis buffer (1% Nonidet P-40, 0.5% sodium
deoxycholate, 0.1% SDS) in the presence of protease inhibi-
tor (SIGMAFAST™ protease inhibitor cocktail tablet, EDTA-
free, Sigma-Aldrich) and phosphatase inhibitor (sodium
orthovanadate, VWR International, Radnor, PA, USA). Cell
lysates were sonicated and centrifuged at 13 500× g for
10 min at 4°C. Protein concentration of the whole cell
lysates was measured using BCA protein assay and equal
amounts of total protein were resolved on 10% polyacryla-
mide via SDS–PAGE. The separated proteins were electroblot-
ted onto nitrocellulose membrane and blocked in 5% milk in
tris-buffered saline with Tween® 20 for 1 h at room tempera-
ture. The membrane was probed with primary antibodies to
Src, p-Src, STAT3, p-STAT3, FAK, p-FAK, p-p130CAS,
p-paxillin, Bcl-2, survivin and Bax (Cell Signaling Technol-
ogy, Danvers, MA, USA) at 4°C overnight. HRP-conjugated
secondary antibodies (Santa Cruz Biotechnology Inc., Santa
Cruz, CA, USA) in combination with SuperSignal West Dura
(ThermoFisher Scientific, Waltham, MA, USA) were used to
visualize proteins of interest with a ChemiDoc Imaging
System (Bio-Rad Laboratories).
Annexin V-FITC apoptosis assay
MIA PaCa-2 cells (2.5 × 105 cells per 60 mm dish) were seeded
and allowed to adhere overnight. After the indicated treat-
ments, both floating and attached cells were collected,
stained with the Annexin V-FITC apoptosis detection kit
(Dyes: Annexin V-FITC and propidium iodide; BioVision,
Milpitas, CA, USA) according to the manufacturer’s
protocol. Cells were analysed in an LSR II flow cytometer (BD
Biosciences).
siRNA transfection
Sub-confluent MIA PaCa-2 cells (5 × 105 cells per dish) were
transfected in 35 mm dishes with 80 nM STAT3, Src or
control siRNA for 24 h according to the manufacturer’s pro-
tocol (Santa Cruz Biotechnology). Cells were treated with
QD232 (5 μM, 4 h), lysed and then blotted for desired pro-
teins as described earlier.
In vitro wound healing (scratch) assay
For BxPC-3 and MIA PaCa-2 cells: Sub-confluent cells (7 × 104
cells per well) were plated in a 96-well plate, allowed to
adhere overnight, and then serum-starved for 24 h. Wounds
were made with a 200 μL pipette tip. Cells were treated with
QD232 (0, 0.05, 0.1, 0.5, 1, 2.5 and 5 μM) in medium con-
taining 10% FBS. Negative control wells received serum-free
medium. After 24 h, cells were fixed with 100% methanol for
10 min and stained with Giemsa nuclear stain (10% Giemsa,
10% methanol and 80% distilled water) for 30 min at room
temperature and washed with distilled water. Stained cells
were imaged using BD Pathway 435 High-Content Bioimager
(BD Biosciences) using 4× objective.
For ASPC-1 and PANC-1 cells (Li et al., 2004): 96-well
plates were pre-coated with collagen (45 μg·mL−1 dissolved in
0.2 N acetic acid) overnight at 4°C, followed by BSA blocking
(2 mg·mL−1 in DPBS for 1 h) at room temperature. Sub-
confluent cells were seeded in serum-free medium and
allowed to adhere overnight. Wounds and treatments were
performed using the protocol described above.
In vitro migration assay
Overnight serum-starved cells (MIA PaCa-2, 75 000 cells per
well) were plated in serum-free medium on the top chamber
of the 24-well plate cell culture inserts fitted with transparent
PET membranes with 8 μm pores (BD Biosciences) and
allowed to lightly adhere overnight. Next day, cells were
treated with QD232 (0.1 and 1.0 μM) in serum-free medium
in the upper chamber. Cells were stimulated to migrate by
adding fresh medium with 10% FBS to the lower chamber for
24 h. Negative control wells received serum-free medium in
the lower chamber. Cells that did not migrate and remained
adherent to the upper surface of the membrane at 24 h were
lightly scraped off using a Q-tip. Cells that migrated to the
lower surface of the membrane were fixed with 100% metha-
nol for 10 min, stained with Giemsa nuclear stain for 30 min
at room temperature and washed with deionized water.
Images from representative fields of the stained membranes
were captured using Nikon DAIPHOT 300 inverted micro-
scope (Nikon Instruments, Melville, NY, USA) with a 10×
objective. Images were quantified using ImageJ software
(http://rsb.info.nih.gov/).
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Imaging
Sub-confluent cells were seeded in a 60 mmdish (MIA PaCa-2;
5 × 105 cells per well) or a 384-well plate (MIA PaCa-2; 5 × 103
cells per well; HFF-1; 8 × 103 cells per well) and allowed to
adhere overnight. MIA PaCa-2 cells in 60 mm dish were
treated with 5 μM QD232 for increasing time periods (10 or
30 min, 1, 4, 8, 12, or 24 h) and imaged live using Nikon
inverted microscope with a 10× objective. Cells in 384-well
plates were treated with 5 or 10 μM of QD232 for 4 h, fixed
with 100% methanol for 10 min and stained with Giemsa
nuclear stain (10% Giemsa, 10% methanol and 80% distilled
water) for 30 min at room temperature and washed with dis-
tilled water. Stained cells were imaged using BD Pathway 435
High-Content Bioimager (BD Biosciences) with 10× objective.
Xenograft studies
All animal care and experimental procedures were in accord-
ance with the USC institutional guidelines, which were in
agreement with the Guidelines for the Care and Use of Labo-
ratory Animals and were approved by the USC Animal Care
and Use Committee, under protocol number 11458. All
studies involving animals are reported in accordance with the
ARRIVE guidelines for reporting experiments involving
animals (Kilkenny et al., 2010; McGrath et al., 2010). A total
of 10 animals were used in the experiments described here.
MIA PaCa-2 cells (1 × 106 cells in a 100 μL suspension of
50% Matrigel/50% DPBS, v/v) were injected subcutaneously
into the dorsal flank of 8-week-old female athymic nude mice
(Simonsen Laboratories, Gilroy, CA, USA). Tumour size was
monitored three times a week through caliper measurement
using the following equation: V = d2 × D/2, where d represents
width and D represents length of the tumour. Mice were
randomly grouped when average tumour size reached
100 mm3. Treatment was administered by i.p. injection in a
100 μL vehicle (5% DMSO, 10% propylene glycol and 85%
saline, v/v) five times weekly. Mice in the treatment group (n
= 4) received doses of QD232 starting from 10 mg·kg−1 body
weight and later increased to 15 mg·kg−1 (from day 10) and
20 mg·kg−1 (from day 19). Mice in the control group (n = 6)
received the vehicle. The study was concluded when average
tumour size in the control group reached 1000 mm3. Mice
exhibiting excessive tumour burden (>1.0 cm3) were
euthanised using CO2 gas. Routine health checks were per-
formed. Body weight of each mouse was measured using a
weighing scale.
Data analysis
Results are shown as means ± SD or means ± SEM as stated in
the figure legends or table subscripts. Unpaired t-test was
performed for data analysis using the online version of
graphpad software (http://www.graphpad.com/quickcalcs/
ttest1.cfm).
Materials
Stock solutions of all compounds were prepared in DMSO
(EMD Chemicals, Gibbstown, NJ, USA) and stored at −20°C.
Further dilutions were made fresh in DPBS or cell culture
media. Gemcitabine hydrochloride and dasatinib monohy-
drate were purchased from LKT Laboratories (St. Paul, MN,
USA). Control samples in all the experiments were treated
with vehicle (0.1% DMSO).
Results
QD232 affects several critical cell-signalling
pathways governing cell migration
and invasion
In order to analyse the effects of QD232 on cellular signal
transduction pathways, we performed a KinexTM (Kinexus,
Vancouver, Canada) antibody microarray proteomic analysis.
Ingenuity Pathway Analysis (IPA) was used to further analyse
the results obtained from the antibody microarray, and the
canonical pathways were ranked in the order of statistical
significance (Supporting Information Fig. S1). It is important
to note that treatment with QD232 did not indiscriminately
affect all survival and migration pathways. This was of sig-
nificance because QD232 did not exert organ toxicity in the
whole animal studies (see below). Treatment of MIA PaCa-2
pancreatic cancer cells with QD232 (1 μM for 24 h) affected
critical cell-signalling pathways involving the Src/FAK
complex (Supporting Information Fig. S1).
QD232 decreases activating phosphorylation
of Src and FAK in pancreatic cancer cells
In order to confirm the results obtained from the KinexTM
antibody array analysis, we analysed the effect of QD232 on
Src and FAK phosphorylation. As expected, treatment of MIA
PaCa-2 and PANC-1 cells with QD232 decreased the activat-
ing phosphorylations of FAK at Y576/Y577, Y397, Y861 and
Y925 in a concentration- and time-dependent manner
(Figure 1A,F,G and Figure 2A,D,E; Supporting Information
Tables S1 and S2). Additionally, treatment with QD232
resulted in decreased phosphorylation of Src at Y416 in
concentration- and time-dependent manner (Y416 is the acti-
vating phosphorylation of Src) (Figure 1B,F, Figure 2B,D,E,
and Supporting Information Fig. S2, Tables S1 and S2).
However, QD232 did not affect the inactivating phosphoryla-
tion of Src (Y527, Figure 1C). Interestingly, the inhibitory
effects of QD232 on Src and FAK were greater and slightly
faster in onset in MIA PaCa-2 cells than in PANC-1 cells. This
was in accordance with our findings reported earlier. It is
important to note that the basal levels of p-Src are lower in
PANC-1 cells than in MIA PaCa-2 cells. As we had shown that
QD232 was slightly more potent in MIA PaCa-2 cells
(Pathania et al., 2014); we selected this cell line for further
mechanistic evaluation of QD232.
Activation of Src promotes the interaction and phospho-
rylation of target proteins, such as paxillin and CAS family
proteins that also bind FAK. Activation and phosphorylation
of p130CAS and paxillin influences focal adhesion turnover,
supporting cell migration. Treatment of MIA PaCa-2 cells
with QD232 resulted in decreased phosphorylation of both
p130 CAS and paxillin suggesting inhibition of cell migration
(Figure 1E).
QD232 treatment results in changes in cell
morphology and inhibits cell migration
QD232 blocks several pathways that support metastasis in
pancreatic cancer cells (Figures 1 and 2 and Supporting Infor-
mation Fig. S2). As expected, QD232 treatment resulted in
morphological changes in pancreatic cancer cells within 4 h
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(Supporting Information Fig. S3A), while similar treatments
did not induce significant morphological changes in HFF-1
cells (Supporting Information Fig. S3B).
Because cell migration precedes metastasis, we tested the
ability of QD232 to inhibit cell migration in the Boyden
chamber. Decreased migration of MIA PaCa-2 cells was
observed in the presence of 1 μM QD232 (Figure 3A,B; Sup-
porting Information Table S3). Inhibition of migration was
confirmed in the wound healing assay, and this difference
was not due to cytotoxicity as determined in cells treated in
parallel (Figure 3C; Supporting Information Table S3).
However, at a higher concentration of 5 μM, the increase in
wound size can be attributed to the toxicity of the com-
pound. QD232 decreased the ability of a panel of serum-
starved pancreatic cancer cells (MIA PaCa-2, PANC-1, BxPC-3
and ASPC-1) to close the wound when stimulated with 10%
FBS (Figure 3D–G and Supporting Information Fig. S4 and
Table S3).
QD232 inhibits cell cycle progression
The Src/FAK complex governs cell cycle progression by regu-
lating several downstream targets (Zhou et al., 2011). QD232
inhibits activity of the Src/FAK complex and therefore should
block cell cycle progression. Treatment of MIA PaCa-2 cells
with QD232 (1 μM, 24 h) resulted in arrest of cells in S-phase
(and slight G2/M). These effects were more prominent at
Figure 1
QD232 decreases phosphorylation of signalling proteins involved in cell migration in pancreatic cancer cells. Treatment of MIA PaCa-2 cells with
QD232 (5 μM) results in inhibition of activating phosphorylations of FAK (A) Src (B), STAT3 (D), p130CAS and paxillin (E) in a time-dependent
manner. Moreover, it does not affect the inactivating phosphorylation of Src (C). QD232 treatment causes a concentration-dependent decrease
in Src, FAK and STAT3 phosphorylation (F and G). Schematic representation of the effects of QD232 on selected cell-signalling pathways (H). (Y419
and Y530 are activating and inactivating phosphorylation sites for human c-Src, respectively. Text and figure refer to Y419 as Y416 and Y530 as
Y527, as labelled on the antibodies received from Cell Signaling Technology, Danvers, MA, USA. Representative blots of three independent
experiments are shown. Summary data are provided in Supporting Information Table S1.
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2.5 μM of QD232. Cell cycle arrest was sustained for 48 h
(Figure 4A; Supporting Information Table S3). Similar results
were observed in PANC-1 cells (Figure 4B; Supporting Infor-
mation Table S3).
QD232 induces apoptotic cell death
The Src/FAK complex regulates several cell-signalling path-
ways governing cell survival, proliferation and death. Apop-
tosis signalling is one of the canonical pathways most affected
by QD232 treatment (Supporting Information Fig. S1).
QD232 induced rapid and sustained inhibition of cancer cell
proliferation resulting in cell death (Pathania et al., 2014).
Here, QD232 (5 μM) caused cell death by decreasing the
expression of major cell survival proteins including Bcl-2 and
survivin after treatment of MIA PaCa-2 cells for at least 12 h
(Figure 4C,D,E; Supporting Information Table S3). Addition-
ally, QD232 increased expression of the pro-apoptotic protein
Bax (Figure 4E; Supporting Information Table S3). Apoptotic
activity of QD232 was further confirmed by Annexin V/PI
staining, which showed that QD232 concentration-
dependently increased the apoptotic population of MIA
PaCa-2 cells (Figure 4F; Supporting Information Table S3).
QD232 inhibits tumour growth in vivo
QD232 was tested in an athymic nude mice xenograft model
in order to determine its in vivo efficacy. The maximum tol-
erated dose of QD232 was determined by a dose-escalating
experiment in athymic nude mice and no significant toxicity
was observed at the highest dose (40 mg·kg−1). Subcutaneous
human pancreatic cancer xenografts (MIA PaCa-2) were
established on the dorsal flank of the immune-deficient mice,
and treated with QD232 or vehicle until average tumour size
in the control group reached 1000 mm3 (31 days). There was
no significant response to QD232 treatment at a dose of
10 mg·kg−1. Therefore, we increased the dose to 20 mg·kg−1.
Treatment with QD232 at 20 mg·kg−1 significantly suppressed
growth of tumours as compared with the vehicle control
group (Figure 5A). Along the course of the 31 day treatment,
average tumour volume increased by 960% in the control
group, while the average tumour volume only increased by
337% in the QD232-treated group, suggesting significant
antitumour activity of QD232 in vivo. Mice were also moni-
tored daily and weighed twice a week to detect potential
drug-related toxicity (Figure 5B). No systemic symptoms of
toxicity such as weakness, weight loss or lethargy were
detected. Major organs were collected after euthanising the
mice (day 31) in order to assess the potential drug-related
toxicities at the cellular level. Samples were fixed in 10%
neutral buffered formalin, embedded in paraffin, and stained
with H&E for histological analysis. Careful examination of
these tissue sections confirmed no signs of histological abnor-
malities in tissue samples taken from QD232-treated mice,
compared with those from control mice (Figure 5C).
QD232 is efficacious in resistant forms
of cancer
Increased Src and FAKphosphorylation are associatedwith the
inherent and acquired resistance to gemcitabine in pancreatic
Figure 2
Treatment with QD232 decreases phosphorylation of FAK, Src and STAT3 in PANC-1 cells. Treatment of PANC-1 cells with QD232 (5 μM) inhibits
activating phosphorylations of FAK (A) Src (B) and STAT3 (C) in a time-dependent manner. (D and E) QD232 treatment results in a concentration-
dependent decrease in Src, FAK and STAT3 phosphorylation. Representative blots of three independent experiments are shown. Summary data
are provided in Supporting Information Table S2.
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cancer cells (Duxbury et al., 2004b; Zhou et al., 2011). QD232
treatment inhibits Src/FAK-mediated cell signalling and is
effective in inhibiting cell proliferation in MIA PaCa-2 cells
either resistant to gemcitabine alone (MIA PaCa-2-GR; IC50 =
2.7 μM) or to both gemcitabine and erlotinib (MIA PaCA-2-
GTR; IC50 = 2.3 μM). These values are similar to its IC50 (2.3 ±
0.2 μM) in parental MIA PaCa-2 cells (Pathania et al., 2014).
The lack of inhibition of STAT3 phosphorylation is one of
the reasons for resistance to dasatinib therapy (Nagaraj et al.,
2010). In our experiments, MIA PaCa-2 cells treated with
Figure 3
QD232 inhibits cell migration. (A) A 24 h treatment with QD232 (1 μM) resulted in decreased migration of serum-starved MIA PaCa-2 cells
through the membrane of a Boyden chamber in the presence of 10% FBS stimulation. Cells were imaged after fixing with methanol and staining
with Giemsa using a Nikon microscope with 10× objective. (B) Quantification of data (means ± SD) shown in (A); effect induced by both
concentrations of QD232 were significantly different from control (10% FBS only); P < 0.05. (C) Cell viability (means ± SD) as determined by MTT
assay of MIA PaCa-2 cells treated with QD232 concentrations that were used in the cell migration assays under identical conditions. (D, E)
Treatment with QD232 for 24 h inhibited closure of wounds stimulated by 10% FBS in serum-starved MIA PaCa-2 (D) and PANC-1 (E) cells in a
dose-dependent manner. Media without FBS was used as a control for the inhibition of wound closure. Cells were imaged after fixing with
methanol and staining with Giemsa using BD Pathway 435 High-Content Bioimager with a 4× objective. Representative images of three
independent experiments are shown. (F, G). Quantification of images (means ± SD) shown in D and E respectively. Images were quantified using
ImageJ software (http://rsb.info.nih.gov/). All concentrations of QD232, except the lowest (0.05μM in F, and 0.05 and 0.1 μM in G), had
significant effects, compared with 10% FBS only; P < 0.05.
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Figure 4
QD232 induces cell cycle arrest and cell death in pancreatic cancer cells. Exposure of MIA PaCa-2 (A) or PANC-1 (B) cells to QD232 resulted in
S-phase (and slight G2/M) arrest in a concentration- and time-dependent manner. Dasatinib was used as a positive control for inducing cell cycle
arrest in pancreatic cancer cells. Treatment of MIA PaCa-2 cells with QD232 resulted in decreased expression of cell survival proteins Bcl-2 (C and
E) and survivin (D), and increased expression of pro-apoptotic Bax (C) in a concentration- and time-dependent manner. (F) Apoptotic cell death
induced by QD232 in MIA PaCa-2 cells was further confirmed by AnnexinV assay. Control and QD232-treated MIA PaCa-2 cells were stained with
Annexin V-FITC and PI and analysed by flow cytometry. Annexin V-negative and PI-negative cells were viable. Annexin V-positive and PI-negative
cells were in early stages of apoptosis, and cells positive for both Annexin V and PI represented cell death by late stages of apoptosis and necrosis.
5 μM of QD232 was used for time course experiments in panel E. Representative data of three independent experiments are shown here. Summary
data for these experiments are provided in Supporting Information Table S3.
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QD232 showed a clear decrease in p-STAT3 after 30 min of
drug exposure and of p-Src in 4 h. However, treatment of the
same cell line with dasatinib significantly decreased levels of
p-Src and not of p-STAT3, after 12 h of exposure (Figure 6A;
Supporting Information Table S4).
QD232 exerts ROS-mediated effects
STAT3 is one of the downstream targets of Src and is directly
activated by Src (Kim et al., 2009). Other signalling pathways
can also affect p-STAT3 levels (Debnath et al., 2012). QD232
induced a robust decrease in Src and STAT3 phosphorylation,
in our experiments. In order to determine if the decrease in
STAT3 phosphorylation by QD232 was due to its effects on
Src, we knocked down Src and re-assessed the effects of QD232
on STAT3 phosphorylation. In MIA PaCa-2 cells, STAT3 is
activated even in the absence of Src, indicating that in this
model, other pathways may be responsible for p-STAT3 levels
(Figure 6B; Supporting Information Table S4). Interestingly,
QD232 was able to decrease STAT3 phosphorylation in Src
knocked downMIA PaCa-2 pancreatic cancer cells (Figure 6B).
This suggests that the effect of QD232 on STAT3 was inde-
pendent of its effect on Src. Moreover, QD232 was able to
decrease Src phosphorylation in STAT3 knocked down cells
(Figure 6C; Supporting Information Table S4), suggesting lack
of a feedback loop from STAT3 to Src. In a cell-free, in vitro,
kinase activity assay of 92 oncogenic kinases (including Src
and FAK), QD232 at 10 μM caused only <25% inhibition or
stimulation of the tested targets. It did not inhibit Src or FAK
in this kinase activity assay (Supporting Information Fig. S5).
These data suggest that the effect of QD232 on Src and STAT3
activation is mechanistically different from dasatinib.
We have previously shown that QD232 rapidly increased
the cellular content of ROS (Pathania et al., 2014). ROS are
known to act as essential second messengers in cells and can
influence many signal transduction pathways with different
kinetics, including Src/FAK signalling (Cunnick et al., 1998;
Tang et al., 2005; Kemble and Sun, 2009). Therefore, we ana-
lysed the effects of QD232 on Src, FAK and STAT3 in the
presence of the antioxidants, N-acetylcysteine (NAC) or glu-
tathione (GSH). QD232 was not able to decrease phosphor-
ylation of Src, FAK or STAT3 in MIA PaCa-2 cells in the
presence of antioxidants (Figure 6D). This suggests that
QD232 exerts ROS-mediated effects on Src/FAK/STAT3 signal-
ling in pancreatic cancer cells.
Discussion and conclusions
Pancreatic cancer is one of the deadliest and most aggressive
diseases with poor prognosis and limited therapeutic options
Figure 5
QD232 suppresses tumour growth in a mouse xenograft model of pancreatic cancer and does not exhibit significant signs of systemic toxicity.
(A) The plot shows the tumour volumes (means ± SD) among the treatment groups over the course of the experiment. Vehicle control and QD232
were administered five times a week (5 days on, 2 days off regimen). Tumour volumes were measured three times a week. (B) Treatment with
QD232 does not result in loss in body weight. (C) Representative micrographs of haematoxylin and eosin (H&E)-stained organ sections. No
significant microscopic changes were detected in major organs after QD232 treatment. Images were taken with Olympus IX73 inverted
microscope at 20× magnification. (D) Representative micrographs of H&E-stained tumour sections. Tumour samples showed obvious areas of
necrosis.
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for most patients (cancer.gov, 2014a). Therefore, there is a
pressing need for more effective treatment strategies for this
disease. Expression and activation of Src and FAK kinases
have been linked to clinicopathological characteristics of
pancreatic ductal adenocarcinoma (Lutz et al., 1998;
Chatzizacharias et al., 2010). Src and FAK act as a complex
and regulate many cellular events including cell proliferation,
survival, adhesion, migration and invasion linked to cancer
progression and metastasis (Summy and Gallick, 2003; Kim
et al., 2009; Bolos et al., 2010). Therefore, targeting pathways
leading to inhibition of the Src/FAK complex and its down-
stream effects is an attractive strategy for developing antican-
cer therapies.
Treatment of pancreatic cancer cells with QD232 resulted
in a robust decrease in phosphorylation of the Src/FAK
complex at several sites (Figures 1 and 2 and Supporting
Information Fig. S2). Autophosphorylation of FAK at Y397
results in its activation and creates a docking site for Src. Once
activated by FAK, Src can further phosphorylate FAK at
various sites resulting in a feedback activation loop (Zhou
et al., 2011). Together Src and FAK function as a protein
complex for regulation of several cellular signal transduction
pathways. QD232 decreased phosphorylation of FAK at
several sites including the autophosphorylated Y397 that acts
as a docking site for Src (Figures 1A,F,G and 2A,D,E). Associa-
tion of Src with FAK results in full activation of Src. In turn,
activated Src phosphorylates FAK at Y576/577 (catalytic
domain) and Y925 (docking site for growth-factor-receptor-
bound protein 2, mediates RAS-MAPK signalling, and Src-
induced epithelial mesenchymal transition) (McLean et al.,
2005). QD232 decreased Src phosphorylation at Y416 (acti-
vating phosphorylation) and Src-directed FAK phosphoryla-
tions at Y576/577 and Y925 (Figures 1A,B,F,G and 2B,D,E).
Moreover, QD232 decreased phosphorylation of FAK at Y861
(Figures 1A,F and 2D), a site that influences tumour vascula-
ture by governing the interaction of FAK with integrins and
regulates FAK’s interaction with p130CAS, promoting cell
invasion (McLean et al., 2005). Decreased FAK-Y861 phos-
phorylation, following treatment with by QD232, led to
decreased phosphorylation of its substrate p130CAS
(Figure 1E). QD232 also decreased phosphorylation of paxil-
lin (Figure 1E), a substrate of the Src/FAK complex that acts as
an adaptor for several proteins involved in cell adhesion
(Bolos et al., 2010).
The decreased Src/FAK phosphorylation was accompanied
by morphological changes in cancer cells (Supporting Infor-
mation Fig. S3A). These morphological changes were not
observed in normal fibroblasts, suggesting that QD232 is
Figure 6
QD232 exhibits ROS-mediated effects on cell-signalling proteins. (A) Unlike dasatinib, QD232 can cause robust decrease in phosphorylation of Src
as well as STAT3. Cells were treated with increasing concentrations of dasatinib for 12 h or with QD232 (5 μM) for 0.5–4.0 h. In cells treated with
dasatinib, there is a clear inhibition of Src phosphorylation, but no effect on p-STAT3. However, QD232 treatment results in complete inhibition
of STAT3 phosphorylation. (B) QD232 decreases STAT3 phosphorylation in Src knocked down MIA PaCa-2 cells suggesting that its effect on STAT3
is independent of its effect on Src. (C) QD232 decreases Src phosphorylation in STAT3 knocked down MIA PaCa-2 cells. (D) Treatment with QD232
in the presence of antioxidants (NAC or GSH) blocked the ability of QD232 to inhibit Src, FAK or STAT3 phosphorylation. Cells were pretreated
for 2 h with antioxidants (10 mM), washed with 1× DPBS and then exposed to QD232 (5 μM, 4 h). Representative blots of three independent
experiments are shown here and summary data for these experiments are shown in Supporting Information Table S4.
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more effective in cancer cells (Supporting Information
Fig. S3B). Several studies have shown that cells lacking FAK
expression migrate poorly compared with normal fibroblasts
(Ilic et al., 1995; Owen et al., 1999; Sieg et al., 2000). QD232
decreased Src/FAK activation (Figures 1 and 2 and Supporting
Information Fig. S2) and hence, inhibited cell migration in
pancreatic cancer cells (Figure 3A,D,E and Supporting Infor-
mation Fig. S4).
Src and FAK also play an important role in the regulation
of the cell cycle progression (Reiske et al., 2000; Shen and
Guan, 2001). Like other inhibitors of Src/FAK, QD232 blocks
cell cycle progression in cancer cells (Figure 4A,B). Further-
more, inhibition of cellular FAK and Src has been linked to
cell detachment that results in apoptosis (Hungerford et al.,
1996; Xu et al., 1996; Beierle et al., 2010). Treatment with
QD232 results in detachment of cancer cells (Supporting
Information Fig. S3) leading to cell death (Figure 4F; Pathania
et al., 2014). This mechanism is supported by QD232-induced
decreased expression of pro-survival proteins including Bcl-2
and survivin (Figure 4C,D,E), and increased expression of Bax
(Figure 4E). Moreover, we previously showed that QD232
activates Fas/FasL and caspases, which further validates that
QD232 treatment results in apoptotic cell death (Pathania
et al., 2014). More significantly, QD232 delays tumour
growth in a mouse xenograft model of pancreatic cancer
without inducing significant deleterious side effects
(Figure 5).
A major limitation of pancreatic cancer therapy is the
development of resistance to currently available therapies
including gemcitabine. The expression and activation of Src
increases from normal pancreas to pancreatitis to pancreatic
adenocarcinoma, in accordance with its role in cancer pro-
gression and metastasis (Lutz et al., 1998; Summy and
Gallick, 2003; Hilbig, 2008). Decreasing Src/FAK signalling
has been shown to restore sensitivity to gemcitabine and
5-FU in pancreatic cancer cells (Duxbury et al., 2004a,b;
Ischenko et al., 2008). QD232 inhibited cell proliferation in
gemcitabine-resistant MIA PaCa-2 cells. Furthermore, Src
inhibitors like dasatinib are being developed for treatment of
pancreatic cancer, but they have limited efficacy as mono-
therapy in clinical settings (clinicaltrials.gov, 2014a–g).
Recent studies have shown that dasatinib-resistant pancreatic
cancer cells have activated STAT3 (Nagaraj et al., 2010). Addi-
tionally, STAT3 reactivation has been linked with sustained
Src inhibition in other types of cancer (Sen et al., 2009). Our
studies demonstrated that QD232 inhibited phosphorylation
of both STAT3 and Src, and that activation of STAT3 was also
inhibited in the absence of Src (Figures 1, 2 and 6B and
Supporting Information Fig. S2). Therefore, QD232 treatment
might be beneficial in resistant forms of pancreatic cancer
exhibiting STAT3 activation.
Sustained Src inhibition results in STAT3 activation by
induction of a homeostatic feedback loop leading to resist-
ance to Src inhibitors (Sen et al., 2009). Conversely, complete
inhibition of p-STAT3 results in Src activation as a result of
induction of a feedback loop (Byers et al., 2009). More impor-
tantly, simultaneous blockade of Src and STAT3 activation has
been shown to be a promising therapeutic approach for
several forms of cancer including pancreatic cancer (Nagaraj
et al., 2011). Our novel inhibitor, QD232, decreased STAT3
phosphorylation in Src knockdown cells and decreased Src
phosphorylation in STAT3 knockdown cells (Figure 6B,C).
Targeting three oncoproteins (Src/FAK and STAT3) and poten-
tially overcoming chemoresistance by a single agent may lead
to improved treatment for pancreatic cancer.
Our data demonstrated that the inhibition of the Src/FAK,
and STAT3 by QD232 was mediated through ROS production
and was not due to direct inhibition of kinase activity
(Figure 6D and Supporting Information Fig. S5). ROS regulate
several cellular events by governing a range of signal trans-
duction pathways. For example, the natural product
manumycin inhibits STAT3 by elevating intracellular ROS in
glioma cells (Dixit et al., 2009). Similarly, phenethyl isothio-
cyanate inhibits STAT3 activation in prostate cancer cells by
generating ROS (Gong et al., 2009). STAT3 deletion itself can
sensitize cancer cells to oxidative stress (Barry et al., 2009).
Additionally, inactivation of Src family tyrosine kinases by
ROS has been reported (Cunnick et al., 1998; Tang et al.,
2005; Kemble and Sun, 2009). Previously, we reported that
QD232 treatment causes immediate and significant increase
in cellular ROS production (Pathania et al., 2014). In this
study, we demonstrated that treatment with QD232 in the
presence of antioxidants did not result in decreased STAT3,
Src or FAK phosphorylation (Figure 6D) suggesting that gen-
eration of ROS is essential for QD232 activity (Figure 7).
In conclusion, we have discovered a novel low MW com-
pound that inhibited the growth of tumours in a mouse
xenograft model of pancreatic cancer and exerted ROS-
mediated decrease in Src/FAK and STAT3 phosphorylation,
resulting in efficient inhibition of cell proliferation, adhesion
and migration, ultimately leading to pancreatic cancer cell
death by apoptosis (Figure 7). Although drugs that individu-
ally and selectively inhibit Src, FAK and STAT3 are under
development, when used as single agents, they tend to
induce resistance. For example, sustained inhibition of Src by
dasatinib results in resistance mediated by STAT3 activation.
Discovery of a single compound that can block the activation
of these three critical signalling pathways simultaneously,
will significantly contribute to more effective treatment and
overcome resistance. Therefore, QD232 can serve not only as
a unique pharmacological probe, but can also be developed
into an effective therapeutic agent for pancreatic cancer, as
monotherapy or in combination with other chemotherapeu-
tic agents.
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Appendix S1 Methods.
Figure S1 QD232 affects several critical cell-signalling path-
ways governing cell migration and invasion. MIA PaCa-2 cells
were treated with QD232 (1 μM) for 24 h, lysed following
Kinexus’s protocol, and screened for 378 pan-specific (protein
abundance) and 273 phospho-site-specific antibodies.
Control and treated cell lysates were labelled with fluorescent
dye and analysed separately on the same chip spotted with
the array of antibodies. Quantitative analysis of the fluores-
cence intensity signal for each target protein was performed
for each sample, and fold-change ratios of treated-to-control
were reported. These data were further analysed using Inge-
nuity Pathway Analysis (IPA) software and the plot displaying
top canonical pathways affected by QD232 treatment was
generated. −log p on the left Y-axis represents the statistical
significance and the pathways are arranged in the order of
their statistical significance. Ratio represents the ratio of
number of signalling proteins affected by the treatment to
the total number of signalling proteins in that pathway
reported in IPA.
Figure S2 QD232 causes rapid decrease in p-Src in MIA
PaCa-2 pancreatic cancer cells. QD232 (5 μM) results in
decreasing phosphorylation of p-Src (A) in a time-dependent
manner without affecting the expression of total Src (B). Cells
were fixed with 0.4% formaldehyde and stained using
primary antibodies for p-Src and Src followed by incubation
with respective secondary antibodies and then counter-
stained with DAPI nuclear dye. Cells were imaged using BD
Pathway 435 High-Content Bioimager (BD Biosciences, San
Jose, CA, USA) using 10× objective. Representative images of
three independent experiments are shown.
Figure S3 QD232 causes rapid change in morphology of
cancer cells, but not of normal cells. (A) 5 μMQD232 resulted
in loss of adhesion and rounding up of MIA PaCa-2 pancre-
atic cancer cells within 4 h of treatment. Cells were imaged
live using Nikon microscope with 10× objective. (B) However,
no change in morphology was observed in normal HFF-1
fibroblasts even at 10 μM treatment with QD232. Cells were
imaged after fixing with methanol and staining with Giemsa
using BD Pathway 435 High-Content Bioimager (BD Bio-
sciences, San Jose, CA, USA) using 10× objective. Representa-
tive images of three independent experiments are shown.
Figure S4 QD232 inhibits cell migration in cancer cells.
QD232 inhibited closure of wounds stimulated by 10% FBS in
serum-starved BxPC-3 (A) and ASPC-1 (B) pancreatic cancer
cells in a concentration-dependent manner after 24 h treat-
ment. Cells were imaged after fixing with methanol and
staining with Giemsa using BD Pathway 435 High-Content
Bioimager (BD Biosciences, San Jose, CA, USA) using 4×
objective. (C, D) Quantification of data shown in A and B,
respectively. Representative images of three independent
experiments are shown. Images were quantified using ImageJ
software (http://rsb.info.nih.gov/).
Figure S5 QD232 does not cause any significant inhibition
in activity of oncogenic kinases in vitro. QD232 (10 μM) does
not significantly inhibit the activity of oncogenic kinases
(including FAK and Src) in a kinase profiling in vitro substrate
assay. Kinase ProfilerTM assay was performed by EMD Milli-
pore, Billerica, MA, USA. Concentration of ATP used in the
assay was Km for each kinase. 10 μM ATP was used for kinases
for which Km was not known.
Table S1 Quantification of data for Figure 1.
Table S2 Quantification of data for Figure 2.
Table S3 Quantification of data for Figure 4.
Table S4 Quantification of Data for Figure 6.
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